How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Controlling glycemia in diabetes remains key to prevent complications in this condition. However, glucose levels can undergo large fluctuations secondary to daily activities, consequently creating management difficulties. The current review summarizes the basics of glucose management in diabetes by addressing the main glycemic parameters. The advantages and limitation of HbA1c, the gold standard measure of glucose control, are discussed together with the clinical importance of hypoglycemia and glycemic variability. The review subsequently moves focus to glucose monitoring techniques in diabetes, assessing advantages and limitations. Monitoring glucose levels is crucial for effective and safe adjustment of hypoglycemic therapy, particularly in insulin users. Self-monitoring of blood glucose (SMBG), based on capillary glucose testing, remains one of the most widely used methods to monitor glucose levels, given the relative accuracy, familiarity, and manageable costs. However, patient inconvenience and the sporadic nature of SMBG limit clinical effectiveness of this approach. In contrast, continuous glucose monitoring (CGM) provides a more comprehensive picture of glucose levels, but these systems are expensive and require constant calibration which, together with concerns over accuracy of earlier devices, restrict CGM use to special groups of patients. The newer flash continuous glucose monitoring (FCGM) system, which is more affordable than conventional CGM devices and does not require calibration, offers an alternative glucose monitoring strategy that comprehensively analyzes glucose profile while sparing patients the inconvenience of capillary glucose testing for therapy adjustment or CGM calibration. The fast development of new CGM devices will gradually displace SMBG as the main glucose testing method. Avoiding the inconvenience of SMBG and optimizing glycemia through alternative glucose testing strategies will help to reduce the risk of complications and improve quality of life in patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“It is well accepted that hyperglycemia in diabetes directly contributes to short/long-term microvascular complications and has a long-term role in the development of macrovascular disease.(5,7) Several mechanisms have been proposed for the adverse vascular effects of hyperglycemia, including increased oxidative stress…”
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812 · cited 1×
“15 Second, HbA1c does not address hypo-glycemia or GV, both of which are associated with adverse clinical outcomes (detailed below).”
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“Two more recent highquality multicenter studies have been conducted to further investigate the role of CGM in T1DM patients treated with multiple daily insulin (MDI) injections.(59,60) The first is the DIAMOND trial, a randomized multicenter study conducted in the United States involving 24 endocrine centers and 158 p…”
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893 · cited 3×
“However, limited evidence from two RCTs suggests a benefit in both T1DM and T2DM patients on multiple daily injections with insulin.(65,66) The rapid increase in FCGM users will provide further crucial data on the role of this glucose monitoring strategy in optimizing glycemic control in diabetes.”
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694 · cited 1×
“4 Interestingly, some of these benefits were observed early such as nephropathy where albuminuria was reduced within 1 year of maintaining good glycemic control.”
The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
Bailey, T., Bode, B. W., Christiansen, M. P., Klaff, L. J., & Alva, S. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0378 · Cited by 685 · cited 1×
“64 FCGM has a number of advantages over conventional CGM, including factory calibration, thus offering a genuine break from capillary glucose testing, long sensor life of 2 weeks, and relatively low costs.”
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“CGM has also been used linked to insulin pumps allowing the development of sensoraugmented pumps that suspend insulin infusion when hypoglycemia is detected or predicted,(48,49) with more sophisticated systems even adjusting for hyperglycemia.(50) In general, CGM studies have shown an improvement in glycemia, measured…”
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 3×
“05).(66) Moreover, hypoglycemia was reduced by 43% in intervention compared with control arm (P < 0.”
Self-citationIncreased mortality of patients with diabetes reporting severe hypoglycemia
McCoy, R. G., Van Houten, H. K., Ziegenfuss, J. Y., Shah, N. D., Wermers, R. A., & Smith, S. A. (2012) · Diabetes Care · doi:10.2337/dc11-2054 · Cited by 539
Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin
Bry, L., Chen, P. C., & Sacks, D. B. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.2.153 · Cited by 523 · cited 1×
“16–19 Therefore, it is important to understand the limitations of HbA1c and supplement glycemic assessment by glucose checks, a view supported by the recent ADA recommendation.”
Miller, K. M., Beck, R. W., Bergenstal, R. M., Goland, R. S., Haller, M. J., McGill, J. B., Rodriguez, H., Simmons, J. H., Hirsch, I. B., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1770 · Cited by 505
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Goto, A., Arah, O. A., Goto, M., Terauchi, Y., & Noda, M. (2013) · BMJ · doi:10.1136/bmj.f4533 · Cited by 492 · cited 1×
“29 Furthermore, accumulating evidence suggests that hypoglycemia is more frequent than initially envisaged, 30,31 even in those classified as having ‘‘preserved hypoglycemic aware-ness’’; therefore, the size of problem may be even bigger than previously projected.”
Glycemic Variability: How Do We Measure It and Why Is It Important?
Suh, S., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.273 · Cited by 439
Hypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381 · cited 2×
“Hypoglycemia is increasingly seen in diabetes given the ever tighter glycemic targets and this complication of therapy can have detrimental effects through a number of mechanisms, including cardiac dysrhythmias, increased production of vascular inflammatory molecules, and an enhanced thrombotic environment (reviewed in…”
Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015) · Diabetes Care · doi:10.2337/dc14-0920 · Cited by 356
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Bergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307 · cited 1×
“54 Retrospective or real-time CGM?”
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
Continuous glucose monitoring sensors: past, present and future algorithmic challenges
Facchinetti, A. (2016) · Sensors · doi:10.3390/s16122093 · Cited by 176
Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes
Weinstock, R. S., DuBose, S. N., Bergenstal, R. M., Chaytor, N. S., Peterson, C., Olson, B. A., Munshi, M. N., Perrin, A. J. S., Miller, K. M., Beck, R. W., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1426 · Cited by 171 · cited 1×
“38 Finally, the association between GV and low glucose levels, including nocturnal hypoglycemia, 39–41 raises the possibility that GV is not an independent predictor of adverse clinical outcome.”
Yu, F., Lv, L., Liang, Z., Wang, Y., Wen, J., Lin, X., Zhou, Y., Mai, C., & Niu, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4332 · Cited by 162
Hernandez, T. L., Van Pelt, R. E., Anderson, M. A., Reece, M. S., Reynolds, R. M., de la Houssaye, B. A., Heerwagen, M., Donahoo, W. T., Daniels, L. J., Chartier-Logan, C., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0515 · Cited by 157
Choudhary, P., Olsen, B. S., Conget, I., Welsh, J. B., Vorrink, L., & Shin, J. J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0324 · Cited by 118 · cited 1×
“CGM has also been used linked to insulin pumps allowing the development of sensor-augmented pumps that suspend insulin infusion when hypo-glycemia is detected or predicted, 48,49 with more sophisticated systems even adjusting for hyperglycemia.”
Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease
Freedman, B. I., Shihabi, Z. K., Andries, L., Cardona, C. Y., Peacock, T. P., Byers, J. R., Russell, G. B., Stratta, R. J., & Bleyer, A. J. (2010) · American Journal of Nephrology · doi:10.1159/000287561 · Cited by 90
Frequency of self-monitoring blood glucose and attainment of HbA1c target values
Elgart, J. F., González, L., Prestes, M., Rucci, E., & Gagliardino, J. J. (2016) · Acta Diabetologica · doi:10.1007/s00592-015-0745-9 · Cited by 51 · cited 1×
“45 FIG.”
Cited by
Diabetic foot ulcers: Classification, risk factors and management
Wang, X., Yuan, C.-X., Xu, B., & Yu, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1049 · Cited by 305
Ajjan, R. A., Heller, S. R., Everett, C. C., Vargas-Palacios, A., Higham, R., Sharples, L., Gorog, D. A., Rogers, A., Reynolds, C., Fernandez, C., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1219 · Cited by 44
Self-citationThe History, Evolution and Future of Continuous Glucose Monitoring (CGM)
Bender, C., Vestergaard, P., & Cichosz, S. L. (2025) · Diabetology · doi:10.3390/diabetology6030017 · Cited by 43
Meng, R., Gu, T., Yang, F., Liu, J., Sun, Q., & Zhu, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01171-2 · Cited by 11
Metadata
- Authors
- Ajjan, R. A.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-05
- Volume
- 19
- Issue
- S2
- Pages
- S-27-S-36
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2617689652
- Cited by
- 97
- References
- 33
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.